Please assess the completion status of the following clinical trial:

Trial Title: Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must ≥ 18 years of age inclusive, at the time of signing the informed consent.~* Participants with severe hemophilia A (FVIII: C\<1%)~* PTPs (Previously treated patients) (≥150 ED (Exposure day)) on prophylaxis treatment before enrollment~* Participants who are immunocompetent. If human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4)+ lymphocyte count \>200/mm\*3~* Participants who are willing to complete an eDiary~* Male participants~* Capable of giving signed informed consent~Exclusion Criteria:~* Any other inherited or acquired bleeding disorder in addition to Hemophilia A.~* Platelet count \< 100,000/mm\*3~* Creatinine \> 2x upper limit of normal~* AST or ALT \> 5x upper limit of normal (AST: aspartate aminotransferase; ALT: alanine aminotransferase)~* The participant has a planned major surgery.~* The participant is currently participating in another investigational drug study, or has participated in a clinical study involving an investigational drug within 30 days of signing informed consent or previous treatment in a clinical phase III study with BAY 94-9027 (now marketed as Jivi).~* Current evidence (by central laboratory) or history of inhibitor to FVIII with a titer ≥ 0.6 Bethesda unit (BU).~* Known hypersensitivity to the drug substance, excipients, or mouse or hamster protein.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Severe hemophilia A patients (Type: OTHER): Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.

Based on this trial design, predict the completion outcome and termination type (if applicable).